Opinion|Videos|November 1, 2023

Results and Key Takeaways From the TriMM-2 Study in Patients With RRMM

Author(s)Rafael Fonseca, MD

Dr Rafael Fonesca reviews data from the TriMM-2 study presented at ASCO 2023 investigating combination talquetamab plus daratumumab for patients with relapsed/refractory multiple myeloma, highlighting a 78% response rate to talquetamab, but noting side effects like CRS and infections.

Episodes in this series

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 1 Case Presentation: A 66-Year-Old Man with Relapsed/Refractory Multiple Myeloma (RRMM)

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 2 Reviewing Treatment Decisions for a 66-Year-Old Man With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 3 Available Treatment Options for Later Lines of Therapy in Patients With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 4 Results and Key Takeaways From the TriMM-2 Study in Patients With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 5 Analysis of Infections and Humoral Immunity in Patients With RRMM Treated With Talquetamab Monotherapy in MonumenTAL-1

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 6 Optimal Sequencing in Patients With RRMM Previously Treated With a BCMA-Targeted Therapy

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 7 Novel Treatments and Targets Under Investigation for Patients With RRMM

Rafael Fonseca, MD, smiles at the camera on a white-and-yellow background.

EP. 8 Clinical Pearls for Community Oncologists Treating Patients With RRMM

Newsletter

Stay up to date on practice-changing data in community practice.

Related to this article

Iberdomide Triplet Improves PFS by 51% in Phase 3 Myeloma Trial

October 8th, 2026

Iberdomide Triplet Improves PFS by 51% in Phase 3 Myeloma Trial

The phase 3 EXCALIBER-RRMM trial demonstrated PFS benefit for iberdomide, daratumamab, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma.

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

VS-7375 Shows Antitumor Activity in PDAC, Other KRAS G12D–Mutant Tumors

ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types

FDA Accepts BLA for Pembrolizumab Biosimilar Candidate FYB206

Durability of PFS and OS Benefit vs. Historical Control

Amivantamab vs. Emerging EGFR Bispecifics in HNSCC